8,700 Studies Reviewed. 87.0% Found Biological Effects. The Evidence is Clear.
Shield Your Body
Whole Body / General

Kaneda E, Kawai T, Okamura Y, Miyagawa S

Bioeffects Seen

Authors not listed · 2025

Share:

This pharmaceutical study was incorrectly classified as EMF research and contains no electromagnetic field exposure data.

Plain English Summary

Summary written for general audiences

This study appears to be about a diabetes/kidney disease medication called empagliflozin, not electromagnetic field (EMF) research. The EMPA-KIDNEY trial found that this drug improved quality of life and reduced healthcare costs for chronic kidney disease patients over 2-4 years. This research has no connection to EMF exposure or wireless radiation health effects.

Why This Matters

This study has been incorrectly categorized in our EMF database. The EMPA-KIDNEY trial investigated empagliflozin, a pharmaceutical treatment for chronic kidney disease, with no electromagnetic field component whatsoever. This highlights a critical issue in EMF research databases - proper study classification is essential for meaningful analysis. When legitimate EMF studies get mixed with unrelated medical research, it dilutes the scientific discourse around wireless radiation health effects. The reality is that EMF research requires precise categorization to identify genuine exposure studies, distinguish between different frequency ranges, and track consistent biological endpoints. Misclassified studies like this one create noise that can obscure the real patterns emerging from decades of EMF research.

Exposure Information

Specific exposure levels were not quantified in this study.

Cite This Study
Unknown (2025). Kaneda E, Kawai T, Okamura Y, Miyagawa S.
Show BibTeX
@article{kaneda_e_kawai_t_okamura_y_miyagawa_s_ce4066,
  author = {Unknown},
  title = {Kaneda E, Kawai T, Okamura Y, Miyagawa S},
  year = {2025},
  doi = {10.1016/j.eclinm.2025.103338},
  
}
DOI: 10.1016/j.eclinm.2025.103338PubMed: 40686671

Quick Questions About This Study

This appears to be a database classification error. The EMPA-KIDNEY trial studied empagliflozin medication for chronic kidney disease patients, with no electromagnetic field exposure component. It should not be included in EMF research collections.
No connection exists between empagliflozin and electromagnetic fields. This sodium-glucose co-transporter 2 inhibitor is a pharmaceutical drug that works through biochemical pathways, not electromagnetic mechanisms. The study examined healthcare costs and quality of life outcomes.
Researchers studied whether empagliflozin (10 mg daily) improved quality-adjusted life years and reduced healthcare costs in 6,609 chronic kidney disease patients over 2-4 years, compared to placebo. No EMF exposure was involved.
While both examine health outcomes, pharmaceutical trials like EMPA-KIDNEY use completely different methodologies than EMF exposure studies. Drug trials focus on biochemical mechanisms, while EMF research investigates electromagnetic field biological interactions through different pathways.
EMF research databases must implement strict classification criteria to separate genuine electromagnetic exposure studies from unrelated medical research. Clear frequency ranges, exposure parameters, and biological endpoints should be required for inclusion to maintain scientific integrity.